United Therapeutics advances new pulmonary hypertension treatment to FDA review
United Therapeutics Corp. is a step closer to getting a new pulmonary arterial hypertension treatment to patients.
The Silver Spring biotech’s New Drug Application for Trevyent, a treatment that uses treprostinil — the same active ingredient in three of United Therapeutics’ existing products — has been accepted by the Food and Drug Administration, the company announced Wednesday.
The FDA will now revi ew the product, a combination of that drug and the technology to inject it subcutaneously,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Sara Gilgore Source Type: news